Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Lisa, Nardelli"'
Autor:
David A, Sallman, Amy E, DeZern, Guillermo, Garcia-Manero, David P, Steensma, Gail J, Roboz, Mikkael A, Sekeres, Thomas, Cluzeau, Kendra L, Sweet, Amy, McLemore, Kathy L, McGraw, John, Puskas, Ling, Zhang, Jiqiang, Yao, Qianxing, Mo, Lisa, Nardelli, Najla H, Al Ali, Eric, Padron, Greg, Korbel, Eyal C, Attar, Hagop M, Kantarjian, Jeffrey E, Lancet, Pierre, Fenaux, Alan F, List, Rami S, Komrokji
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(14)
Approximately 20% of patients withThis was a phase Ib/II study to determine the safety, recommended phase II dose, and efficacy of eprenetapopt administered in combination with azacitidine in patients withFifty-five patients (40 MDS, 11 AML, and four
Autor:
Rami S. Komrokji, Javier Pinilla-Ibarz, Daohai Yu, Lisa Nardelli, Christopher Cubitt, Xiuhua Zhao, Hugo F. Fernandez, Alan F List, Jeffrey E. Lancet
Publikováno v:
Blood. 118:2604-2604
Abstract 2604 BACKGOUND There is no standard salvage chemotherapy regimen for relapsed or refractory (RR) AML. Receptor activated tyrosine kinases such as c-kit, c-fms and PDGFR are known targets of inhibition by imatinib mesylate (IM) and are freque